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Abstract
Background and Aims: Because of the extremely low neoplastic progression rate in Barrett’s esophagus, it is difﬁ  cult to 
diagnose patients with concomitant adenocarcinoma early in their disease course. If biomarkers existed in normal squamous 
esophageal epithelium to identify patients with concomitant esophageal adenocarcinoma, potential applications would be 
far-reaching. The aim of the current study was to identify global gene expression patterns in normal esophageal epithelium 
capable of revealing simultaneous esophageal adenocarcinoma, even located remotely in the esophagus.
Methods: Tissues comprised normal esophageal epithelia from 9 patients with esophageal adenocarcinoma, 8 patients 
lacking esophageal adenocarcinoma or Barrett’s, and 6 patients with Barrett’s esophagus alone. cDNA microarrays were 
performed, and pattern recognition in each of these subgroups was achieved using shrunken nearest centroid predictors.
Results: Our method accurately discriminated normal esophageal epithelia of 8/8 patients without esophageal adenocarci-
noma or Barrett’s esophagus and of 6/6 patients with Barrett’s esophagus alone from normal esophageal epithelia of 9/9 
patients with Barrett’s esophagus and concomitant esophageal adenocarcinoma. Moreover, we identiﬁ  ed genes differentially 
expressed between the above subgroups. Thus, based on their corresponding normal esophageal epithelia alone, our method 
accurately diagnosed patients who had concomitant esophageal adenocarcinoma.
Conclusions: These global gene expression patterns, along with individual genes culled from them, represent potential 
biomarkers for the early diagnosis of esophageal adenocarcinoma from normal esophageal epithelia. Genes discovered in 
normal esophagus that are differentially expressed in patients with vs. without esophageal adenocarcinoma merit further 
pursuit in molecular genetic, functional, and therapeutic interventional studies.
Abbreviations: BE: Barrett’s esophagus; EAC: esophageal adenocarcinoma; NE: normal esophageal epithelium; 
SNCPs: shrunken nearest centroid predictors; BE-CA: normal esophageal epithelia from patients with Barrett’s esophagus 
and esophageal adenocarcinoma; N-N: normal esophageal epithelia from patients lacking esophageal adenocarcinoma or 
Barrett’s; BE-only: normal esophageal epithelia from patients with Barrett’s esophagus alone.
Introduction
One of the greatest challenges in the management of Barrett’s esophagus (BE), the precursor lesion of 
esophageal adenocarcinoma (EAC), is to expeditiously identify patients who have early EAC and to predict 
those who are most likely to develop EAC. The rate of progression to cancer (0.4%–1% per year) is very 
low, making this challenge particularly difﬁ  cult (Reynolds et al. 1999; Cameron, 1997). Moreover, in the 
surveillance of BE, a meticulous endoscopic search is often performed to histologically identify grossly 
normal-appearing dysplastic or cancerous lesions. However, the value of this type of systematic surveillance 128
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has been questioned, due to its low sensitivity and 
speciﬁ  city (Conio et al. 2003). Thus, from a purely 
practical standpoint, it would be advantageous to 
be able to identify patients with malignant esoph-
ageal lesions simply by biopsying their normal 
squamous esophagus.
The presence and degree of dysplasia constitute 
the most widely accepted measure of neoplastic 
risk in Barrett’s esophagus. However, signiﬁ  cant 
problems have emerged demonstrating the need 
for improved progression risk biomarkers. These 
problems include poor interobserver reproducibil-
ity of dysplasia interpretation and inconsistent rates 
of progression as well as regression of dysplasia, 
both of which have made it difﬁ  cult to develop 
national surveillance guidelines (Rana and 
Johnston, 2000; Conio et al. 2003; Reid et al. 
2000). Flow cytometry has shown promise in 
detecting a subset of patients who do not have 
high-grade dysplasia (HGD) but do have an 
increased risk of progression (Reid et al. 2000). 
The human genome project has yielded high-
throughput methodologies for the computer analy-
sis of data, which provide volume and quality 
control required to select clinically useful biomark-
ers (Taramelli and Acquati, 2004; Varmus and 
Stillman, 2005; Yoshida, 1999). 17p (p53)-loss of 
heterozygosity (LOH) has also shown potential as 
a molecular biomarker (Reid et al. 2003). In addi-
tion, methylation of p16, IN × 3 and HPP1 have 
been shown to predict progression to HGD and 
EAC (Hardie et al. 2005) (Geddert et al. 2004) 
(Schulmann et al. 2005). Molecular alterations 
have been found in Barrett’s metaplasia which 
reveal a ﬁ  eld effect in premalignant metaplastic 
mucosa, but not in normal epithelium. For example, 
aneuploidy and loss of heterozygosity have been 
observed in metaplastic mucosa from Barrett’s 
patients with dysplasia or adenocarcinoma (Blount 
et al. 1993; Boynton et al. 1991; Raskind et al. 
1992; Reid et al. 1987). Similarly, p53 tumor sup-
pressor gene point mutations have been reported 
in Barrett’s metaplasia (Casson et al. 1994; Huang 
et al. 1993; Meltzer et al. 1991), and altered pro-
moter DNA methylation has also been described 
for some tumor suppressor genes in Barrett’s 
esophagus (Eads et al. 2000a; Kawakami et al. 
2000; Klump et al. 1998; Wong et al. 1997). In 
contrast, most published studies to date report no 
DNA alterations (e.g. point mutations, methylation, 
or loss of heterozygosity) in normal squamous 
esophageal epithelium from patients with esophageal 
cancer. Corn et al. (Corn et al. 2001) reported E-
cadherin methylation in Barrett’s esophagus 
specimens and esophageal adenocarcinoma, but 
not in normal esophageal epithelium. Another 
study showed that the expression of a panel of 23 
genes capable of differentiating between Barrett’s 
esophagus and esophageal adenocarcinoma was 
unable to distinguish between the normal epithelia 
of Barrett’s metaplasia and adenocarcinoma 
patients (Brabender et al. 2004). One notable 
exception was the study by Eads et al. which found 
methylation of the CALCA, MGMT, and TIMP3 
genes in the normal esophagus of a subset of 
patients with Barrett’s-associated esophageal dys-
plasia and adenocarcinoma (Eads et al. 2001).
cDNA microarrays promise more accurate pre-
diction than do classical clinical diagnostic tools 
(such as histologic categorization). However, the 
main challenge posed by microarrays is to con-
struct meaningful classiﬁ  ers based on gene expres-
sion proﬁ  les, using appropriate bioinformatics 
tools. A number of bioinformatics tools have been 
proposed, including artificial neural networks 
(Selaru et al. 2002a), hierarchical clustering (Selaru 
et al. 2002b; Zou et al. 2002) and principal com-
ponents analysis (Mori et al. 2003; Selaru et al. 
2004). In this paper, we have used shrunken near-
est centroid predictors (SNCPs), an analysis 
technique adapted from classical nearest centroids 
predictors to gene microarray analysis (Tibshirani 
et al. 2002).
The aim of the current study was to identify 
global gene expression patterns as well as individual 
genes in normal esophageal epithelium capable of 
revealing simultaneous esophageal adenocar-
cinoma, even located remotely in the esophagus.
Materials and Methods
Patients and tissues
Six patients with BE alone, 9 with BE and con-
comitant EAC, and 8 with neither BE nor EAC 
were included in this study. The 8 patients without 
BE or EAC had had endoscopy for unrelated indi-
cations, such as peptic ulcer disease, but had 
undergone endoscopic biopsy of the gastroesoph-
ageal junction that was histologically normal. In 
all cases, biopsies from grossly normal-appearing 
squamous esophageal epithelium at least 7 cm 
proximal to the upper limit of the Barrett’s mucosa 
were included in the study. None of the patients 129
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with BE alone had concomitant dysplasia. Fresh 
NE (normal esophagus) biopsy specimens were 
immediately frozen and stored in liquid nitrogen 
until further use. Matching morphologic controls 
were obtained from the same sites as the research 
specimens and were examined by hematoxylin and 
eosin staining by an expert gastrointestinal pathol-
ogist at the University of Maryland. Informed 
consent was obtained from all patients under an 
institutionally approved research protocol.
Location of the normal squamous 
esophageal biopsies
The NE areas biopsied were grossly normal, with-
out any endoscopic evidence of esophagitis or 
reﬂ  ux changes. In patients with obvious mass 
lesions in their esophagus, biopsies were obtained 
at least 7 cm proximal to these lesions. Similarly, 
biopsies from BE patients were performed at last 
7 cm away from the area that showed endoscopic 
evidence of Barrett’s esophagus. In patients lacking 
BE or EAC, biopsies were performed from areas 
that did not show any gross endoscopic abnor-
malities. Finally, all NE specimens were analyzed 
histologically, and there was no evidence of any 
metaplasia or other changes found in any of these 
NE samples.
cDNA microarray production 
and hybridization
Detailed protocols for glass slide coating, cDNA 
clone preparation and veriﬁ  cation, microarray 
printing, post-printing slide processing, RNA 
extraction, RNA amplification, labeling and 
hybridization have been published by our labora-
tory (Selaru et al. 2002b; Xu et al. 2002; Zou et al. 
2002).
RNA Extraction, Ampliﬁ  cation, 
and Labeling of the aRNA Probe
Total RNA (3–20 µg) was extracted from freshly 
frozen tissue using an RNeasy kit (Quiagen, 
Valencia, CA) and ampliﬁ  ed using the AmpliScript 
T7-ﬂ  ash transcription kit (Epicentre, Madison, 
WI). Labeling was performed on 6 µg of aRNA by 
incorporating Cy3- or Cy5-labeled dCTP using 
random primers and Superscript reverse transcrip-
tase (Xu et al. 2002). The resulting probes were 
puriﬁ  ed with a Microcon microcentrifuge ﬁ  lter 
device and recovered in a volume of 25 µl. The 
reference probe was prepared from an equimolar 
mixture containing aRNAs from eight human 
malignant cell lines, as described previously. 
Microarray preparation was performed as described 
(Selaru et al. 2002b; Xu et al. 2002; Mori et al. 
2003).
Microarray normalization
We adapted an algorithm for normalizing microar-
ray data that improves its accuracy and dynamic 
range (Yang et al. 2002). Both within-slide and 
inter-slide normalization were accomplished: in 
this fashion, local distortions in signal and back-
ground intensity within different regions of a slide, 
as well as overall differences in hybridization or 
labeling efﬁ  ciencies between slides, were over-
come. We determined that our within-slide nor-
malization performs optimally when 4 blocks are 
used as the normalization unit (each block being 
produced by a different microarray pin). We 
assumed that each group of 4 blocks was equivalent 
in average signal intensity and range to the next 
group of 4 blocks on the array. Thus, we utilized 
8 normalization units per slide. This assumption 
was based on an optimization strategy in which we 
tested groups of 1, 2, 4, 8, and 16 blocks as the 
normalization unit, which showed that the 4-block 
unit performed with the least inaccuracy when a 
random number generator was used to produce the 
8,064 values on a microarray slide (data not 
shown). Thus, this normalization method (Yang 
et al. 2002) consisted of 3 steps: intensity-
dependent normalization within each slide, scale 
normalization within each slide, and inter-slide 
normalization.
Shrunken nearest centroid predictor 
(SNCP) model
This method is an adaptation of classical nearest 
centroids prediction analysis, tailored speciﬁ  cally 
to microarray data (Tibshirani et al. 2002). Each 
centroid is comprised of weighted averages of 
genes (elements) on the microarray for a particular 
diagnostic category, or “class.” Thus, the centroids 
each contained 8,064 elements, since there were 
8,064 genes on each microarray. Gene weighting 
was directly proportional to the raw average expres-
sion value, but inversely proportional to the standard 
deviation (i.e. the variability) of expression value 
within a given class. Centroids were then shrunken 130
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by adjusting the threshold value, which removed 
genes with lower weighted averages (thus yielding 
a smaller set of relevant genes). Gene expression 
variations below a certain threshold value were 
made equal to zero and ignored. Thus, shrinkage 
consisted of moving the centroid towards zero by 
threshold, and setting it equal to zero when it drops 
completely (Tibshirani et al. 2002).
The choice of ∆ (amount of shrinkage) was 
dependent upon 2 variables: 1. prediction error 
minimization; 2. the number of genes that are left 
in the model. More speciﬁ  cally, when all the 
genes on the microarrays are used, the prediction 
error is signiﬁ  cant. During the process of data 
ﬁ  tting, the SNCP model excludes outliers, i.e. 
genes that are not usable for the prediction. It is, 
however, possible to achieve the minimum pre-
diction error for a range of ∆s. In this particular 
case, the model can predict the predeﬁ  ned catego-
ries using a variable number of genes. Under 
these conditions, the smaller the ∆, the higher the 
number of genes left in the model, and vice 
versa.
Internal validation of results was performed 
using cross-validation. The value of K (fold cross-
validation number) was set by default at 10; 
therefore, we performed a 10-fold cross-validation. 
In this 10-fold cross-validation, the specimens were 
randomly assigned to 10 groups. Nine of the ten 
groups were used for training, while the prediction 
is made on the 10th group. This procedure is 
repeated 10 times. For example, in the Normal-
Normal versus Normal-Cancer comparison, 
training is done on 16 specimens, and then the 
model predicts the 17th specimen.
Permutation analysis
SNCPs are mathematical models that learn by 
example. In other words, SNCPs identify a centroid 
for every group in the comparison. New specimens 
are classiﬁ  ed by calculating the distance between 
the new specimen and each of the centroids. The 
specimen is classiﬁ  ed into the class whose centroid 
is closest to the specimen. Ideally, the SNCPs 
should be tested on a test set, composed of speci-
mens that were not used during training. This, 
however, may prove difﬁ  cult when a small number 
of specimens are available for the study. One 
method to circumvent the need for a test set, while 
ensuring statistical signiﬁ  cance, is permutation 
analysis.
Permutation analysis is a statistical technique 
used to calculate the chances of obtaining classi-
ﬁ  cation results purely by chance. The analysis 
consists of randomly permuting the specimen 
labels and constructing classiﬁ  ers (SNCPs) to 
categorize the specimens. In the current study, 
permutation resulted in randomly assigning spec-
imens to one of two categories: N-N (NE specimens 
from patients lacking EAC or BE) and BE-CA (NE 
specimens from patients with Barrett’s esophagus 
and concomitant esophageal adenocarcinoma). We 
subsequently chose the SNCP model with the low-
est prediction error. We repeated this procedure 
100 times. In all 100 random permutations, SNCPs 
were unable to learn the 2 categories correctly (with 
an error = 0). The mean group error for the 100 
permutations was 0.36. This ﬁ  nding demonstrates 
that the possibility that our SNCP learned the 2 
categories (N-N and BE-CA) correctly by chance 
alone was less than 1 in 100.
Results
In the current study, we sought to determine 
whether the SNCP strategy could be used to iden-
tify gene expression patterns or individual genes 
as biomarkers to distinguish between the normal 
esophagus of patients with, vs. without, accompa-
nying EAC. SNCPs discovered both broad patterns 
and individual genes that were highly accurate in 
their ability to identify whether or not a patient had 
accompanying remotely located cancer.
In our initial application of this strategy, we 
considered NE biopsy specimens of both subjects 
with completely normal esophagi (Normal-Normal, 
or N-N) and patients with BE but without EAC 
(BE-alone) together as a single group, which we 
compared to NE biopsy specimens of patients with 
Barett’s esophagus with concomitant EAC (BE-
CA). Centroids were 100% accurate in predicting 
which subject or patient was in which group in this 
comparison, as shown in Figure 1. A list containing 
195 genes was generated, based on their differen-
tial expression between normal esophagi from 
normal patients and normal esophagi from patients 
with EAC. Table 1 contains a few of these genes, 
with already known links to cancer.
In an effort to further narrow the number of 
variables involved in the difference between NE 
biopsies from patients with concomitant EAC vs. 
subjects without EAC, we also compared NE from 
subjects without esophageal disease vs. NE from 131
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EAC patients only (i.e. excluding noncancer 
subjects with BE). This comparison revealed the 
accuracy of centroids in distinguishing these two 
subgroups, as shown in Figure 2.
The SNCPs also generated visual displays of 
centroids, showing which genes were overexpressed 
and which were underexpressed in NE from patients 
with vs. those without accompanying EAC. The 
genes in these displays are arrayed in order of 
decreasing differential expression, with the most 
differentially expressed genes at the top and the least 
differentially expressed genes at the bottom. One 
such typical centroid is displayed in Figure 3.
Genes represented in a shrunken centroid derived 
by comparing NE tissues between cancer and non-
cancer patients are shown in Table 1. Among them 
are many genes with previous links to esophageal 
cancer or to cancers in general: histone biomarkers, 
gravin, HLA-DRA, keratin 8 (KRT8), glutathione 
peroxidase 2 (GPX2), the mitotic checkpoint protein 
kinase BUB1B, the progestin-induced protein DD5 
and transglutaminase 3.
Discussion
The rate of progression to cancer among Barrett’s 
cohorts (0.4%–0.5% per year in some studies, 0.5 
to 1% per year in other studies) is small, making 
it highly important to identify patients who 
will imminently or ultimately develop cancer 
(Reynolds et al. 1999; Cameron, 1997). Moreover, 
sampling error may entirely miss molecular or 
histologic changes that occur only in Barrett’s 
metaplastic mucosa. Thus, it would be very useful 
to be able to identify patients with concurrent 
esophageal neoplastic progression merely by 
sampling their normal esophagus.
Previous studies have compared gene expression 
patterns among normal, metaplastic, and cancerous 
esophageal epithelia (Guillem et al. 2000; Lu et al. 
2001; Selaru et al. 2002b; Xu et al. 2002). Moreover, 
Figure 1. Predicted diagnoses in comparison of NE from EAC patients vs. patients with either BE only or no BE. Patients with EAC, to the 
left of and on the vertical line, were diagnosed correctly in every case, as were all control patients without any lesion (to the right of the 
vertical line). Red, likelihood of being an EAC patient; blue, likelihood of being a noncancer patient.132
Selaru et al
Bioinformatics and Biology Insights 2007:1
Table 1. Selected genes identiﬁ  ed by comparison of NE from patients with EAC (N with T) vs. without EAC 
(N without T).  Threshold value set at 2.7; N with T: gene score in the group of patients with esophageal 
adenocarcinoma; N without T:  gene score in the group of patients without esophageal adenocarcinoma. Gene 
identiﬁ  ers and gene names are shown in the two leftmost columns.
Gene ID  Gene Name  N with T   N without T 
AB003476 gravin  −0.7322 0.4707
NM_005319  H1 histone family, member 2 (H1F2)  0.5907  −0.3797
XM_004416  H2A histone family, member L (H2AFL)  0.5384  −0.3461
NM_003519  H2B histone family, member C (H2BFC)  0.5062  −0.3254
NM_002273 keratin  8  (KRT8)  0.3834  −0.2465
NM_015902  progestin induced protein (DD5)  −0.3112 0.2001
NM_003516  H2A histone family, member O (H2AFO)  0.2322  −0.1493
XM_009572  transglutaminase 3 (TGM3)  −0.2078 0.1336
NM_019111  major histocompatibility complex, class II, DR alpha (HLA-DRA)  0.1695  −0.109
AF107297  mitotic checkpoint protein kinase BUB1B (BUB1B)   −0.0626 0.0402
NM_002083  glutathione peroxidase 2 (gastrointestinal) (GPX2)  0.0614  −0.0395
Figure 2. Predicted diagnoses in comparison of NE from EAC patients vs. control subjects (patients with neither BE nor EAC). Patients with 
EAC, to the left of the vertical line, were diagnosed correctly in every case, as were all control subjects patients without any lesion (to the 
right of the vertical line). Blue, likelihood of being a control subject; red, likelihood of being an EAC patient.133
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a recent study by Wang, S et al. suggested that gene 
expression patterns in Barrett’s esophagus are 
signiﬁ  cantly closer to gene expression patterns in 
esophageal adenocarcinoma than to expression 
patterns in normal esophagus. This ﬁ  nding  somewhat 
alarmingly implies that Barrett’s esophagus is 
biologically closer to cancer than to normal 
esophagus (Wang et al. 2006). However, these 
studies have consisted of direct comparisons of these 
different types of esophageal epithelia to each other. 
In the current study, a different approach was 
undertaken: i.e., a comparison was made of the normal 
esophageal epithelia from patients at differing stages 
of esophageal neoplastic progression. This study 
found unique molecular signatures in normal 
esophageal epithelium that reﬂ  ected concomitant 
neoplasia elsewhere in the esophagus.
The potential biologic ramiﬁ  cations of our study 
are far-reaching. The field effect found near 
esophageal tumors in surrounding normal epithe-
lium has been well-described (Eads et al. 2000b; 
Eads et al. 2001). A recent study by Brabender et al. 
(Brabender et al. 2005) identiﬁ  ed a ﬁ  eld effect by 
using a gene expression panel. In the current study, 
Figure 3. Centroids from comparison between NE of patients with vs. without accompanying EAC. Overexpressed genes are designated 
by rightward-extending bars; those that are underexpressed protrude to the left. Red centroid, NE specimens from subjects with EAC; green 
centroid, NE from patients without EAC. This plot demonstrates that genes underexpressed in noncancer patients are overexpressed in 
EAC patients, and vice versa. SNCP threshold = 2.7.134
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biopsies of normal esophagus were obtained at 
least 7 cm away from the tumor or Barrett’s 
esophagus. The current findings suggest that 
esophageal cancer exerts a greater inﬂ  uence on the 
normal esophageal epithelium than previously 
known or suspected. While molecular alterations 
in histologically normal squamous esophageal 
epithelium have previously been described adjacent 
to cancers, the current ﬁ  ndings suggest that altera-
tions in gene expression and gene expression pat-
tern accompanying cancer can affect large portions 
of the normal squamous esophagus. We postulate 
that the development of esophageal adenocarci-
noma is accompanied by widespread molecular 
phenotypic alterations that involve the entire nor-
mal squamous esophageal epithelium.
The SNCP-based approach applied in the 
current study offers a number of advantages over 
other analytic techniques. These include the ability 
to differentiate among multiple specimen groups; 
the potential for rapid translation to the clinical 
setting; a low likelihood of overﬁ  tting, yielding a 
low probability of erroneous diagnoses in new, 
independent datasets; and the capacity to yield a 
reduced number of diagnostic genes, which can 
themselves be developed as individual biomarkers 
as well as the basis for further molecular genetic 
studies (Tibshirani et al. 2002).
In the current study, genes positioned the highest 
in centroids discriminating normal tissues from 
noncancer vs. cancer patients were both interesting 
and relevant. For example, among the most highly 
ranked genes were members of the histone families 
(Table 1).
As single-gene predictors, histone biomarkers 
were accurate in distinguishing between accompa-
nying cancer and its absence. Histones are basic 
nuclear proteins responsible for the nucleosome 
structure of chromosomal ﬁ  bers in eukaryotes. 
Apart from promoter hypermethylation, modiﬁ  ca-
tion of histone proteins is the second major com-
ponent of epigenetic transcriptional control. DNA 
methylation and histone acetylation are integrally 
linked. Methylation is catalyzed by a family of 
DNA methyltransferases. DNA methyltransferases 
recruit histone deacetylases, leading to histone 
deacetylation and transcriptional repression. 
Methylated DNA is also recognized by a family of 
methylated DNA-binding proteins, which recruit 
histone deacetylases and ATP-dependent chromatin 
remodeling proteins, resulting in a tightly con-
densed chromatin structure and gene inactivation. 
Additional links between the “histone code” and 
the “cytosine methylation code” are increasingly 
evident (Johnstone, 2002; Kouraklis and Theocharis, 
2002; Marks et al. 2001).
In addition, alterations of proteins in the histone 
acetyltransferase family (e.g. CREB-binding pro-
tein and p300) are associated with cancers of the 
breast, colon, liver, and hematopoietic system. Of 
particular relevance to the current ﬁ  ndings, histone 
H4 is hyperacetylated in early stages of esophageal 
cancer cell invasion, and thereafter changes to a 
hypoacetylated state according to the degree of 
cancer progression (Toh et al. 2003). These results 
suggest that a dynamic equilibrium between his-
tone acetylase and deacetylase activities is dis-
rupted in esophageal carcinogenesis, implying that 
an interaction may exist between hyperacetylation 
of histone H4 and histone deacetylase 1 expression 
(Toh et al. 2003).
Similarly, by applying differential display to 
esophageal tumor and matched normal esophageal 
samples, histone H3.3 was identiﬁ  ed among 49 
cDNA ddPCR clones from esophageal cancers 
(ECs) (Graber et al. 1996). Histone H3.3 was 
overexpressed in 4/6 ECs, but not in paired normal 
mucosa. Only 5/13 normal human cell lines from 
various organs, but 11/12 human cancer cell lines 
(including 9 of 9 adenocarcinoma lines) overex-
pressed H3.3 (Graber et al. 1996). Histones H3 and 
H4 were deacetylated in gastric cancer cell lines 
showing aberrant methylation of CHFR, a mitotic 
checkpoint gene, suggesting a role for histone 
deacetylation in methylation-dependent gene 
silencing (Satoh et al. 2003).
Another gene identiﬁ  ed in the current study was 
HLA-DRA. Major histocompatibility complex 
(MHC) molecules are of central importance in 
regulating the immune response against tumors. 
Loss of expression of HLA class II molecules on 
tumor cells affects the onset and modulation of the 
immune response through lack of activation of 
CD4
+ T lymphocytes. In part, loss of expression is 
caused by mutations as shown for large B-cell 
lymphoma (Jordanova et al. 2003). A recent study 
found downregulation of HLA-DRA in invasive 
cancers compared to dysplastic cervical lesions 
(Chil et al. 2003).
We also observed a strong predictive value of 
keratin 8 (KRT8). KRT8 belongs to the intermedi-
ate ﬁ  lament family and associates with keratin 18 
to form a heterotetramer of two type i and two type 
ii keratins. Its phosphorylation on serine residues 135
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is enhanced during EGF stimulation and mitosis. 
Dysregulation of keratin 8 is associated with 
esophageal carcinogenesis (Boch et al. 1997; 
Glickman et al. 2001a; Glickman et al. 2001b; Salo 
et al. 1996).
Additional genes with known relevance to 
human cancer identified by this SNCP model 
included glutathione peroxidase 2 (GPX2), the 
mitotic checkpoint protein kinase BUB1B, and the 
progestin-induced protein DD5. As expected, 
BUB1B was expressed at high levels in the normal 
esophageal tissues of patients without cancer and 
underexpressed in patients with cancer. BUB1B is 
a component of the mitotic checkpoint that delays 
anaphase until all chromosomes are properly 
attached to the mitotic spindle. In BRCA2-deﬁ  cient 
murine cells, BUB1 mutants potentiate growth and 
cellular transformation (Davenport et al. 1999). In 
addition, mutations in human BUB1B have dem-
onstrated a dominant negative effect by disrupting 
the mitotic checkpoint when transfected into 
euploid colon cancer cell lines (Davenport et al. 
1999). Thus, BUB1B is a candidate tumor suppres-
sor gene in the esophagus whose downregulation 
in normal esophageal tissue is associated with can-
cer development.
Transglutaminase 3, which was underexpressed 
in the normal tissue of tumor patients in our study, 
was recently found to be downregulated in esoph-
ageal squamous cell carcinoma and head and neck 
squamous cell carcinoma by cDNA microarray 
studies comparing cancer and matching normal 
tissue (Luo et al. 2003).
In conclusion, the current study diagnosed 
patients with remote esophageal neoplasia based 
on biopsies of their remote normal epithelium alone, 
and provided a minimal list of genes necessary to 
do so. This proof-of-principle study establishes a 
theoretical basis to identify cancers in other organs 
by studying gene expression patterns or other 
molecular signatures in their matching normal 
epithelia. In addition, by shrinking the number of 
genes needed to arrive at a correct diagnosis, the 
current work showcases an approach to identify 
smaller numbers of genes worthy of further research 
from microarray data, both as biomarkers and for 
biologic or functional studies.
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